INTRODUCTION
Tyrosine kinase inhibitors targeting BCR/ABL have revolutionized the
treatment of CML, changing its prognosis from an overall survival of 5
years to near normal life-expectancy. 3,6 However,
TKIs are associated with potentially serious complications, such as
pleural effusion, pneumonitis, and vascular and metabolic disorders.1,2 Bosutinib is a BCR/ABL inhibitor used in frontline
treatment of CML or in treatment of chronic, accelerated, or blast phase
CML resistant or intolerant to prior TKIs. 3-6 The
most common side effects are gastrointestinal, followed by
thrombocytopenia and abnormal liver function tests.5However, there have been cases reporting pulmonary injury related to
bosutinib. 7 Here, we discuss a case of
bosutinib-induced interstitial lung disease and pleural effusion.